These results were corroborated by correlation analyses, comparing the posterior probability scores obtained for each signature with PAM50-derived scores for basal-like, HER2-enriched, luminal A, luminal B and normal-like breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.